Overview

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Status:
Completed
Trial end date:
2014-08-07
Target enrollment:
Participant gender:
Summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer